$150.00
In stock
| Quantity | Discount (%) | Price |
|---|---|---|
| 1 | — | $150.00 |
| 3 | 53.33 % | $70.00 |
| 6 | 56.67 % | $65.00 |
| 12+ | 60 % | $60.00 |
Free bacteriostatic water with every order.
Research suggests CJC-1295 with DAC may enhance endogenous growth hormone secretion and support anabolic signaling in laboratory studies. This synthetic peptide contains 29 amino acids and is designed as an analog of growth hormone–releasing hormone (GHRH). It is engineered to activate somatotroph cells in the pituitary gland.
Structural modifications, including substitutions of four amino acids, are believed to improve peptide stability while preserving receptor affinity.
The addition of the Drug Affinity Complex (DAC) includes a lysine derivative attached to the C-terminus. This modification is thought to extend circulating half-life by increasing plasma protein binding.
Preclinical research indicates this may prolong activity for several days. It also helps maintain functional interaction with GHRH receptors.
Use our Research Peptide Storage Guide — Laboratory Use Only — to ensure proper handling and stability for controlled experimental applications. Not for human consumption, therapeutic, or diagnostic use.
Chemical Formula: Sequence-dependent (modified growth hormone–releasing peptide analogue with DAC conjugation)
Molecular Weight: ~4,000–5,000 g/mol (varies based on modification and DAC attachment)
CAS Number: Research designation / Assigned upon structural registration
Structure: Synthetic analog of growth hormone–releasing hormone (GHRH) conjugated with Drug Affinity Complex (DAC) technology to extend plasma half-life
Form: Lyophilized peptide powder
Solubility: Soluble in sterile water or buffered aqueous solution
Stability: Stable when frozen; prolonged activity after reconstitution due to DAC modification
Half-Life: Extended half-life (days to approximately one week) compared to non-DAC variants
Storage: Store refrigerated at 36–46°F (2–8°C); protect from light and moisture
Binds to pituitary GHRH receptors and stimulates prolonged pulsatile growth hormone secretion
Drug Affinity Complex (DAC) binding increases circulatory stability and duration of action
Stimulates downstream insulin-like growth factor-1 production through endogenous GH release
Supports protein synthesis, tissue repair, and metabolic regulation via GH-mediated pathways
Studied for sustained increases in GH and IGF-1 levels compared to short-acting analogs
Investigated for improvements in lean mass support and reduction in adiposity markers
Explored for enhanced repair signaling in musculoskeletal and connective tissue models
Evaluated for improved metabolic efficiency and lipid utilization in research settings
Clinical and preclinical data indicate:
Significant elevation in pulsatile GH release
Sustained increase in IGF-1 levels
Dose-dependent endocrine response
Studies demonstrate:
Increased lean muscle mass markers
Reduced fat mass in research models
Improved body composition over extended administration
Evidence suggests:
Enhanced protein synthesis signaling
Improved connective tissue repair markers
Increased collagen production in tissue models
Research shows:
Minimal suppression of natural GH pulsatility when used appropriately
Stable pituitary responsiveness over repeated dosing cycles
Hormonal effects persist due to extended half-life
Temporary fluid retention, joint stiffness, mild injection site irritation
Temporary abdominal bloating, mild gastrointestinal discomfort
Transient increases in blood glucose in sensitive individuals
IGF-1 levels, fasting glucose, blood pressure, fluid retention markers
Dosing is generally individualized and may require gradual titration
Independent laboratory testing confirms purity and composition
Purity
Batch
Date
